Alnylam to Webcast Presentations at Upcoming May Investor Conferences

Rhea-AI Summary

Alnylam Pharmaceuticals (NASDAQ: ALNY) announced key presentations at three upcoming conferences. Management will provide company overviews at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 11:20 am PT in Las Vegas, at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 am ET virtually, and at the UBS Global Healthcare Conference on May 25, 2022, at 10:00 am ET in New York. Live audio webcasts will be available on the company’s website, with replays accessible within 48 hours.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

• BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 11:20 am PT (2:20 pm ET) at the Encore Hotel in Las Vegas
• H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 7:00 am ET, being held virtually
• UBS Global Healthcare Conference on Wednesday, May 25, 2022 at 10:00 am ET at the Lotte New York Palace Hotel in New York

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran) and Leqvio^® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005116/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals is traded under the stock symbol ALNY on Nasdaq.

When will Alnylam present at the BofA Securities Healthcare Conference?

Alnylam will present at the BofA Securities Healthcare Conference on May 11, 2022, at 11:20 am PT.

Is there a live webcast for Alnylam's presentations?

Yes, Alnylam will have live audio webcasts available on their Investors website for each presentation.

What date will Alnylam present at the H.C. Wainwright Global Investment Conference?

Alnylam will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 am ET.

Where is the UBS Global Healthcare Conference taking place?

The UBS Global Healthcare Conference will be held at the Lotte New York Palace Hotel in New York on May 25, 2022.